13F Pro quality score
Rank #2,260 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Sonoma Pharmaceuticals, Inc. (SNOA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SNOA at 36.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,260 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2027), Sonoma Pharmaceuticals, Inc. reports quarterly revenue of $6.4M, net income of $-330.0K, an operating margin of -0.6%. Top institutional holders of SNOA by reported 13-F value include RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SNOA trades on the Nasdaq exchange and files with the SEC under CIK 1367083. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sonoma Pharmaceuticals, Inc. directly from SEC EDGAR.